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The  human  placenta  is  a  critical  life-support  system  that nourishes  and  protects  a rapidly  growing  fetus;  a
unique organ,  species  speciﬁc  in  structure  and function.  We  consider  the pressing  challenge  of  providing
additional  advice  on the  safety  of  prescription  medicines  and  environmental  exposures  in  pregnancy  and
how  ex  vivo  and  in  vitro  human  placental  models  might  be  advanced  to reproducible  human  placental
test  systems  (HPTSs),  reﬁning  a weight  of evidence  to  the  guidance  given  around  compound  risk  assess-
ment  during  pregnancy.  The  placental  pharmacokinetics  of xenobiotic  transfer,  dysregulated  placentallaNet
uman placenta
eproductive toxicology testing
Rs
function  in  pregnancy-related  pathologies  and  inﬂux/efﬂux  transporter  polymorphisms  are  a  few  caveats
that could  be  addressed  by HPTSs,  not  the  speciﬁc  focus  of  current  mammalian  reproductive  toxicology
systems.  An international  consortium,  “PlaNet”,  will  bridge  academia,  industry  and  regulators  to  con-
sider  screen  ability  and  standardisation  issues  surrounding  these  models,  with proven  reproducibility
for  introduction  into  industrial  and  clinical  practice.Please cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
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. Introduction
The human placenta is a critical life-support system that nour-
shes and protects a rapidly growing fetus. The structure and
unction of the human placenta is unique [1]; although rats and
abbits are valid models in the evaluation of potential teratogens,
nterpretation of their transplacental xenobiotic transfer data is
recarious. The fetus is potentially vulnerable to xenobiotics that
ross the placental barrier, which either cause direct damage to the
etus, or indirectly affect embryo development by interfering with
ormal placental function.
Even subtle alterations of the fetal-placental environment may
ave a lasting effect on health in later life and so create a signif-
cant economic burden on healthcare economies. Understanding
ifferences in how xenobiotics are handled by the human placen-
al barrier in the diseased state, compared to normal pregnancy,
s also a pressing concern (see below). Hence, there is a need to
valuate evidence for differences and consider how HPTSs might
e adapted to meet future niche study demands. The uteropla-
ental compartmentalisation of biopharmaceuticals is most likely
ifferent in humans, since such compounds are often handled by
eceptor-mediated endocytosis that differs in other mammals; and
he relevance of these medicines will expand in the future [2,3].
elow, we outline several HPTSs that could be advanced to stan-
ardised applications for use in toxicology testing.
. Consideration of human placental test systems (HPTSs)
.1. Added value to mammalian testing
Currently zebraﬁsh larvae and stem cell models are becoming
ccepted worldwide as a pre-screening tool for embryofetal devel-
pmental endpoints. These models are beginning to complement
ammalian reproductive toxicology testing, conducted much later
n the drug development lifetime [4–6]. However, the zebraﬁsh
nd stem cells lack a placenta. In order to add a further weight
f evidence to the mammalian regulatory studies, there are plans
o develop human placental assays. A human placental testing plat-
orm may  help ﬁll this technology gap (see Fig. 1). The human
lacenta is a readily available, ethically unproblematic human tis-
ue that could be used to assess placental effects and human
ransplacental transfer, subject to conforming to national and insti-
utional guidelines and the standards set by the Declaration of
elsinki [7]. This declaration guides physicians and researchers in
he ethical principles of handling human subjects, human tissue
nd associated data, to safeguard the health and interests of peo-
le. Professionals must act primarily in the interests of patients.
hilst the declaration accepts that experimentation on humans is
n inevitable part in the advancement of medicine, it upholds the
nterests of the patient as a precedent above advancements of sci-
nce and society. It deﬁnes the usefulness of medical research in
he development of prophylactic, diagnostic and therapeutics, as
ell as in providing an understanding of disease aetiology. Con-
ent must be achieved, but only if the participant is able to make
n informed choice without coercion; and where processes are also
ubject to local statute.
Careful thought is needed to address many caveats in the
ntroduction of a new human testing program. For instance, the
esponses to toxins are sometimes dependent on genetic predispo-
itions affected by ethnic diversity and environmental conditions
8–10]. Since ethnic make-up and the environment that local pop-Please cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
lations are exposed to vary enormously within and between
ations, this will affect the cohort demographics of the local obstet-
ic clinic and therefore the recruits to associated research centres
here the placentas are used. It is unknown how such uncontrolled PRESS
xicology xxx (2016) xxx–xxx
circumstances might inﬂuence variability of placental function,
so research development into the utilisation of human placental
tissue needs a study design inclusive of a much wider global diver-
sity. Thus, the complexity and multi-faceted nature of toxicological
testing in the context of regulatory procedures and industrial prac-
tices would require a scale of expertise and cooperation beyond
a few national research centres for the evaluation of risk where
human placentas are being evaluated. This paper considers the
establishment of an international partnership amongst academia,
the pharmaceutical industry, standardisation institutes, and the
regulators, to (i) review our understanding of human placental
transfer processes of xenobiotics; (ii) consider the current state-of-
the art in human placental models, emerging bio-physical sensing
technology and mathematical modelling; (iii) consider short-term
scientiﬁc missions between academia, industry and regulators, tri-
alling pilot studies, harmonising practices, writing standardised
protocols and training a global network of laboratories in best prac-
tice; and (iv) to present outcomes of selected human placental test
systems (Fig. 1).
2.2. International placentology network
A network called “PlaNet” (placentology network) is being
formed, bringing under one global safety umbrella different facets
of chemical effects on fetal survival, growth, function and devel-
opment, building a critical mass of international cutting-edge
expertise in experimental human placental test systems (HPTSs),
pharmacology, toxicology, drug delivery and mathematical mod-
elling. This umbrella will additionally cover the global education
and training in chemical safety testing with human placenta-based
techniques. PlaNet aims to engage academics with the regulatory
authorities, reproductive toxicology societies and the pharmaceuti-
cal and biotechnology industries, to steer the HPTSs and associated
modelling approaches towards standard operating procedures,
connected to meaningful screening assays, recognised by the reg-
ulators for routine compound testing. As a part of these efforts, the
proposed network will also consider innovative methods towards
reducing the number of animals used as drug safety models, while
improving the reliability of the data.
3. Relevance and timeliness
Standardised HPTSs would provide species relevant data and
enable a consideration of placental functional and transfer effects
of xenobiotics. They would deliver additional evidence to com-
plement rat and rabbit reproductive toxicology data and newly
emergent zebraﬁsh larvae and stem cell functional data used in
pharmaceutical testing. With this evidence, medicines labelling
could be written on a ﬁrmer basis for the informed beneﬁt of obste-
tricians and patients. Proposed changes in OECD guidelines will
soon necessitate a consideration of manufacturers to engage in ani-
mal  and in vitro testing of chemicals. Standardised HPTSs may offer
a cost effective means of providing data to assist in safety data sheet
writing by the chemical industry.
3.1. Reproductive toxicology testing in the pharmaceutical
industry
Reproductive toxicity refers to the adverse effects of a substance
on any aspect of the reproductive cycle. Due to the complexity of
the mammalian reproductive cycle, it is hard to model the whole
cycle in a single in vitro system in order to detect chemical effectsnetwork (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
on mammalian reproduction [11]. Development and reproductive
toxicology testing (DART) studies in rats and rabbits form the main
basis for regulatory assessment of the potential effects of pharma-
ceuticals on the developing fetus. Current approaches assessing the
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tig. 1. Demonstrating the academic capacity for human placental test systems am
xploited for the purpose of advancing new methods in industrial reproductive tox
afety of pharmaceuticals in women of child bearing potential are
onducted in animals using highly regulated agreed predictive pro-
edures following regional or international guidelines to assess the
isk of a compound on the developing fetus. There has been a recent
ecision by the US Food and Drug Administration (FDA) to increase
wareness of the effects of prescription medicines on women dur-
ng pregnancy [12]. However, all toxicity testing (in vivo, in vitro and
n silico) has limitations when extrapolating from animals to the
uman or even from cell to whole organism. More approaches are
eing investigated, both in vitro and in silico to improve the weight
f evidence of data in order to build a bigger picture for risk assess-
ent for a compound. Safety testing is of worldwide concern and
herefore international acceptance of new approaches and models
s an important element in addressing the challenge. A key issue
s to increase the screen ability of test compounds within new test
ystems as well as to prove the reproducibility of the models.
.2. Environmental exposure to chemicals in pregnancy
Aside from pharmaceuticals, a wider spectrum of environmen-
al and consumer chemicals may  affect fetal development and have
een associated with adverse reproductive, neurobehavioral and
mmunological effects later in the child’s life. Improved assessment
f the human health risk posed by chemicals therefore requires
dditional information about placental transfer and hazardous
ffects of substances [13]. The collective expertise of PlaNet should
elp to identify appropriate techniques and procedures which can
rotect the mother and the fetus from health risks arising from their
xposure to environmental and consumer chemicals. The proposal
o progress human placental systems from a pure academic interest
o recognised regulated test systems will be extremely innovative
nd will necessitate close scrutiny of their usefulness along with
ight validation.
The toxicology of industrial chemical testing is guided by OECD
egulations relating to agrochemicals, with OECD TG 421 cov-
ring reproduction and developmental toxicity screening testing
14]. These recommendations have recently changed, requiringPlease cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
n assessment of “internal dose” in hazard assessments, leading
o the internal dose metric studies in animals. With a height-
ned requirement for toxicokinetic analysis, there are triggers in
his regulation for the requirement to study endocrine disruption, the current PlaNet (placentology network) research centres and how this will be
y testing.
covering some of the sensitive periods of development, including
the pre-natal period [15,16]. Only short duration in vivo animal
studies are expected to be undertaken; and increasingly, in vitro
methods are being used in this ﬁeld, including the use of mouse
and human stem cells. Since the human placenta is a key endocrine
organ in pregnancy, the future use of HPTSs could bring added bene-
ﬁt in the elucidation of any disruptive effects on placental endocrine
function. The European Chemicals Agency has accepted the OECD
guidelines, with a principled view by the European Union of ban-
ning the production and import of endocrine disruptors [15]. A new
EU draft guidance suggests that every registered industrial chem-
ical produced at levels of 10 t/annum or more must undergo tests
for potential effects on development and reproduction. The docu-
ment states that the level of testing, including considerations on the
number of species tested and the recommendations and require-
ments for extended one-generation reproductive toxicity studies
(EOGRTS) should be dependent on the thresholds reached for ton-
nage of production. These practices relate to the EU marketplace;
elsewhere global expectations of the chemical industry vary.
3.3. Information permitting informed patient decisions
To optimise safe drug administration in Europe, the European
Medicines Agency (EMA) has suggested that new rules for con-
tent and format of labelling for drugs in pregnancy are required
to include “narrative sections on risk summary, clinical consid-
eration, and a data section including more detailed information”
[17]. Under EMAs Pregnancy and Lactation Labelling Rule (PLLR)
this has already led to a reconﬁguration of safety data informa-
tion, based upon existing in vivo mammalian data; but new formats
will remain devoid of any potential further functional data until
regulatory acceptance of zebraﬁsh, stem cell and human placenta
models becomes a full reality. With the help of leading interna-
tional academic and clinical research centres, medicines’ regulators
and representatives of the pharmaceutical industry, PlaNet could
enhance the quality of information leading to such labelling by pro-
viding additional information on human placenta and effects andnetwork (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
human-speciﬁc maternofetal transfer pharmacokinetics. Likewise,
The FDA has recognised the limitations of the current drug labelling
system and safety testing practices that potentially compromise
clinical care of patients and their children and is also recently
ARTICLE IN PRESSG ModelRTX-7319; No. of Pages 12
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Fig. 2. Cross sectional diagrammatic representations of the anatomy of the term human placenta. (a) Shows the juxtaposition of maternal blood ﬂow to the villous tree,
which  emanates into the intervillous space from spiral arteries, thought to empty into the centre of a cotyledon, followed by percolation through the spaces between multiple
villi  (light shaded arrows), before returning for uterine vein drainage (dark arrows). (b) Demonstrates the probable maternal-side intervillous space ﬂow geometry in the
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ndothelium that separates maternal and fetal blood, enabling a more effective diff
uided on the need for the integration of animal and human test-
ng data from reproductive toxicology testing [18]. A European
uideline (EMA; Guideline on risk assessment of medicinal prod-
cts in human reproduction and lactation – from data to labelling;
dopted by CHMP 2008) also recommends reporting data on phar-
acokinetics of placental transfer of the medicinal product and/or
ts metabolites [17].
.4. Filling the knowledge gap
Pharmaceuticals are in use by over 60% of women of childbear-
ng potential in the developed world [19]. Often they, are taken after
onception, but before pregnancy has been detected. All medica-
ions on the market will have undergone a package of reproductive
oxicology testing, including effects on F1 generation development
o sexual maturity and mating and behavioural development, in
ammalian models. However, many pharmaceutical risk assess-
ents air on the side of caution in their guidance for administration
f medicines during pregnancy and breast feeding. With the excep-
ion of medicines required to prevent serious maternal morbidityPlease cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
nd survival, most pharmaceuticals taken to treat chronic medi-
al conditions are withdrawn on the guidance of the obstetrician
nce pregnancy is conﬁrmed. This is based on the labelling advice
uch as “not tested in pregnant women – avoid in pregnancy”,ultiple maternal cannulae into the intervillous space at a considerable depth (circa
ighting the vasculosyncytial membrane, a thinning of the syncytium and capillary
, which is particularly important to hydrophilic solute transfer processes.
found in information sheets for the sheer majority of prescribed
items and over-the-counter products. This happens regardless of
the fact that regulated mammalian reproductive toxicology testing
has been performed. Therefore, one ultimate key goal of PlaNet is to
bring into discussion a framework to help make available placen-
tal risk-assessments, that provide more meaningful information to
clinicians and patients, permitting more informed choices regard-
ing the continued taking of speciﬁc medications [20].
4. Placental anatomy
4.1. Placental circulations at the maternofetal interface
Blood circulates between fetus and placenta via the umbili-
cal cord which houses two  arteries and one vein. The umbilical
arteries carry blood from the fetus to the placenta, ﬁrstly branch-
ing as two divergent patterns across the chorionic plate, then
dividing extensively to generate the sub-chorial placental villous
trees [21]. The placental microcirculation is present within these
villi [22]. Stem arterioles within stem villi branch to form arte-network (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
rioles within mature intermediate villi, dividing further to from
sinusoidal capillaries within terminal villi [22]. The villi are the
nutrient exchange units of the placenta and their outermost cell
layer in contact with maternal blood is the syncytiotrophoblast, a
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Fig. 3. Maternofetal permeability of the human placenta to inert hydrophilic solutes
by  diffusional transfer. Reproduced with the kind permission of Prof C.P. Sibley.ARTICLETX-7319; No. of Pages 12
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ransporting epithelium that exchanges solutes between mater-
al blood in the intervillous space and the vascularised fetal
lood. Where the fetal capillaries are most proximal to maternal
lood, at the “vasculosyncytial membrane” (Fig. 2c), the capillary
ndothelium and the syncytiotrophoblast are the only cell layers
orming a barrier [23]. Here, trophoblast cells are displaced, as
re the organelles of the syncytiotrophoblast. Hence, the length
f the pathway for transfer between the two circulations is min-
mised, ensuring transplacental diffusion is particularly efﬁcient for
ydrophilic solutes (Fig. 2c) [24]. Conversely, maternal blood is not
ascularised in the human placenta. The functional exchange unit
f the human placenta is the cotyledon, comprising of an entire vil-
ous tree. Blood enters the intervillous space (IVS) and surrounds
he frond-like villi from transformed spiral arteries [25]. Maternal
xygenated blood, replete in nutrients, enters the IVS from a trans-
ormed spiral artery into the centre of each cotyledon, encountering
any terminal villi during its percolation towards the decidual
eins, where it drains from the IVS (Fig. 2a). Within the villous tree,
etal blood returns to the fetus within a vascularised venous system,
raining blood from the sinusoidal capillaries, which ﬂows through
enules in the villous tree and then through subchorial veins, taking
ith it dissolved solute acquired from the maternal circulation. On
he chorionic plate, fetal placental veins converge and increase in
iameter, extending across the chorionic plate, ultimately converg-
ng into the single large vein of the umbilical cord which returns
xygen and nutrient rich blood to the fetus [26].
.2. Human placental pharmacokinetics
EMA  notes that it “..is important to consider the transfer of sub-
tances entering the embryo-foetal compartment, and that to do
o, separate studies are needed to assess placental transfer” [27].
herefore understanding the pharmacokinetics of human placen-
al transfer is of key importance to appreciating fetal exposure
n the human. Placental transfer efﬁcacy varies between species,
ttributable to variation in placental structures, pore size and
aemodynamic factors [1]. In the human placenta, as a rough guide,
f a hydrophilic molecule exceeds 5 KDa (a molecular radius equiv-
lent to circa 1–2 nm), placental transfer by simple diffusion in the
aternofetal direction is effectively zero, dictated through steric
indrance at the paracellular route, which has a mean notional pore
adius of approximately 10 nm (Fig. 3) [28–30].
In contrast, lipophilic molecules transfer across the placenta
ore like gases. Their transfer is less constrained by species
ifferences in placental barrier morphology, but instead highly
nﬂuenced by the factors associated with placental blood ﬂow,
hich acts to negate their transmembrane equilibrium [31]. For
hese lipophilic molecules, (i) the rate of fetoplacental ﬂow; (ii) the
aternal and fetal blood ﬂow geometries and (iii) the occurrence
f villous blood shunts are the main drivers of transfer efﬁcacy [32].
ifferent ﬂow geometries confer upon the placenta differences in
ransfer efﬁciency between species, which are unrelated to the spe-
iﬁc histological nature of the barrier [33].
For monoclonal antibodies with a molecular weight in the order
f 150KDa, the Fc (FcRn) receptor is a speciﬁc transport mecha-
ism; its expression widely varies between species, making the
uman ex vivo placental perfusion the model a vital choice in
tudying biopharmaceutical maternofetal pharmacokinetics [34].
urthermore, for non-human primates and humans, IgG placental
ransfer is low in the ﬁrst trimester, increasing in the early second
rimester, reaching highest levels late in the third trimester [35].
his contrasts markedly with rodents, where the yolk sac placentaPlease cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
onstitutes a possible earlier pathway in IgG maternofetal trans-
er by FcRn transport mechanisms [36,37]. Thornburg and Faber
emonstrated that guinea pig yolk sac vessel ligation prevents
amma  globulin transfer to the fetus [38]. However, the human yolksac is only present within the ﬁrst trimester, becoming markedly
degenerate by week 9 [39]; a period in which human fetal antibody
accrual is in any case very low [35,37].
4.3. Current regulatory embryo and fetal development
assessment guidance
In relation to pharmaceuticals, the FDA has outlined non-clinical
data needed for the integrated assessment of in human develop-
ment and reproductive risk, citing general toxicology, reproductive
and developmental toxicology, and pharmacokinetic studies [18].
There is some ﬂexibility in reporting risk relating to the type and
extent of available toxicology data, depending on the product’s
biological actions, the test systems available for studying the com-
pound and the positivity of the data [18].
HPTSs, therefore have the potential to be coupled to assays that
might add value to risk assessments by providing new relevant and
validated studies, with outputs that could feed into the decision
tree process. To reach this goal, their predictive in vitro mechanistic
relevance must be proven to link to an in vivo effect and the relation-
ship between the in vivo outcome and the in vitro test result must
be explained [40]. In a recent concept paper, EMA has highlighted
that laboratories that participate in large collaborative studies are
in a great position to publish methods in regulatory texts, as they
will gain more valuable experience with the method as a whole.
The agency encourages facilitation towards gaining laboratory and
product speciﬁc validation and the implementation of methods innetwork (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
other laboratories [41].
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.4. Network objectives
The highly interdisciplinary network will critically assess exist-
ng HPTSs (see below) for development, through the implemen-
ation of best practice in standards with proven reproducibility,
cceptable for systematic safety testing of pharmaceutical and con-
umer products used during pregnancy. PlaNet aims to capacity
uild internationally, with training for new investigators in the use
f techniques, once harmonised. Another objective is to comple-
ent existing mammalian toxicology databases with a publicly
ccessible database containing human placental data, linked to
otential toxicology mechanisms and associated testing technol-
gy. There is also a need for the promotion of integration of clinical,
xperimental and computational in silico tools for understanding
hemical transfer and effects on placental function in healthy and
ompromised pregnancies. The network plans to publish “off-the-
eg” protocols for use by industry in toxicology testing, although
ome of the non-cell line techniques will need to be performed
ithin academic research centres, where access to fresh human
lacental tissue is possible via associated obstetric departments. In
he latter case, trained academic centres with regulatory labora-
ory accreditation will be able to act as contracting consultancies
or testing panels of compounds, as required by industry.
A wide range of HPTSs are already in use by the academic
ommunity on a variety of research themes, including xenobiotics
ransfer and pharmacokinetics [42]; blood ﬂow [43], nutrient and
on transfer [44,45]; oxygenation effects and osmolality regulation
46,47]; endothelial signalling [48], angiogenesis and vasculo-
enesis [49]; inﬂammation and immunology [50,51]; placental
rophoblast cell turnover, multi-nucleation, differentiation and
egeneration [52]; DNA damage and repair, genotoxicity and car-
inogenesis [53]. Below we give an overview of the state-of-the-art
n the current employment of HPTSs.
.5. Ex vivo dual placental perfusion of the human placenta
Currently, this is the only HPTS capable of providing reliable
ransfer data of xenobiotics across the human placenta. The level
f organisation of the tissue with this model is far more likely to
pproximate to in vivo performance than working with oversimpli-
ed tissue slices, trophoblast cells, or isolated membrane vesicles
31]. The disadvantages of the model are that (i) its use is prone to
 high preparation rejection rate, through intra- and post-partum
reakages occurring randomly throughout the lobule and if per-
usion is not established within a reasonable timeframe; (ii) it is
 relatively expensive model to employ; (iii) only one lobule can
ractically be perfused at any one time; (iv) it only lends itself reli-
bly to acute perfusion time periods of no more than 6–7 h; (v)
alidated perfusion of second trimester placentas has not yet been
chieved. The schematic representation of one particular design of
n ex vivo human placental perfusion rig is given in Fig. 4. Perme-
bility measurement using one or more cotyledons is an integration
f the effects of transfer into all the perfused fetal vessels [54–56].
hilst preventing any insight into speciﬁc barrier characteristics
t different foci of the villus tree, or across the endothelium of dif-
erent fetal vessels, the permeability estimates obtained through
he ex vivo perfusion are nonetheless representative of the intact in
ivo macro placental structure.
There have been several attempts to devise an acceptable
ethod of ex vivo human placental perfusion across many decades
n the twentieth century. Internationally, we have come to adopt
he description of this model given by Schneider, Dancis and PanigelPlease cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
ublished in the early 1970’s, where the authors describe a mas-
ered adaptation of intervillous space perfusion, complementing
he already established method for fetoplacental villous perfusion,
sing several cannulae which simply pierced the decidual plate to PRESS
xicology xxx (2016) xxx–xxx
mimic  spiral artery blood ﬂow irrigating the outside villous tree
[57,58]. A depiction of what this probably means to IVS ﬂow is given
in Fig. 2b and how this compares to in vivo IVS ﬂow (Fig. 2a).
Although the placenta has a remarkable capacity to enter
into anaerobic respiration and “partial metabolic arrest” during
ischaemia and low oxygenations [59], several attempts have been
made to address the imperfection of super-oxygenation given to
the tissue during ex vivo perfusion, which is employed to compen-
sate for a poor oxygen carrying capacity in blood-free conditions
[60]. The ideal methodology of oxygenation is still undetermined
and varies enormously between research centres [61,62]. As men-
tioned above, the cotyledon is the functional unit of the placenta
described from the fetal villous aspect, but the number of these
included on ex vivo perfusion will vary. In addition the juxtapo-
sition of maternal cannulae within the IVS (Fig. 2b) means that
maternal and fetal ﬂow could mismatch, with variation between
preparations. Hence, in order to standardise placental transfer data
for a compound, transfer rates of the xenobiotic is standardised
against that of an inert lipophilic marker, antipyrine [63], or poten-
tially against test compound enantiomers. Due to protein binding of
some drugs, the presence of albumin concentration in the maternal
circulation and the species of origin might also affect the pharma-
cokinetics of transfer [64].
It has been possible to model nutrient transfer across microvil-
lous (apical) and basal membranes of the syncytiotrophoblast,
with the knowledge of activities of transporters from microvillous
and basal microvessicle experiments [65–67]. Likewise, eventu-
ally this should also be possible for all known drug uptake and
efﬂux transporters present in the human placenta. This information
could enable an integrated evaluation of complex drug–drug and
drug-transporter interactions and physiologically based pharma-
cokinetics through in silico modelling to predict fetal safety, related
to maternal pharmaceutical dosing. Real transfer data from ex vivo
perfusions could then be used to test the accuracy of this modelling.
In addition to studying compound transfer, the ex vivo dual
perfusion model is useful in elucidating effects on placental
endocrinology, inﬂammation, metabolism, placental immunology;
and perhaps even fetal vascular effects, since the fetoplacental vas-
culature is in continuity with the fetal vasculature and shares the
same milieu [59,68–72]. A key challenge of the network is in devis-
ing and disseminating a uniﬁed protocol for ex vivo perfusion that
best suits industrial and regulatory requirements for chemicals
safety testing.
4.6. Villous explant culture
This is a more chronic tissue culture model allowing a study
into effects of a compound on the regenerative capacity of the
trophoblast to form a syncytiotrophoblast, or the effect of a xeno-
biotic on the steady state endocrinology, structure and function
of the trophoblast layer. Tiny fragments of dissected villous tissue,
approximately 3 mm in length are cultured in suspension on porous
mesh support inserts, at the meniscus of culture medium, held
within a twelve well culture plate. The culture medium is replaced
daily, and at 24 h a surge in hCG release, followed by a very low level
of release at day 2, coincides with entire syncytiotrophoblast shed-
ding. From days 2–4 a new syncytiotrophoblast forms and during
this time basal levels of hCG become released into the tissue culture
medium. By day 5, hCG release is normal and plateaus thereafter.
Tissue histology is assessed to ensure regeneration of the syncy-
tiotrophoblast shell, or effects on a known regenerated structure.
Lactate dehydrogenase release levels report on disturbances in tro-network (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
phoblast architecture. Functional studies might include effects on
amino acid, or other nutrient uptake; culture-conditioned medium
can be assayed for the release of paracrine and inﬂammatory
mediators [73]. Optimisation and standardisation of protocols to
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Fig. 4. One example of an equipment design for ex vivo human placental dual perfusion. Here the placental lobule is mounted within a double ring structure, with part of
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vhe  chorionic plate cannulated at the artery and vein (downward facing), correspo
urrently international variability in perfusion rig design, the number of maternal can
egimen, the ﬂow rates used and the adoption of open-, or closed-circuit perfusion 
aintain syncytial trophoblast layer integrity is needed for suc-
essful translation. This model can be applied to human placental
issue from all available gestational ages.
.7. Chorionic plate artery & vein wire myography
Fetoplacental vascular resistance is normally maintained at very
ow levels, particularly as gestation progresses, ensuring adequate
lood ﬂow to the developing fetus [74]. This technique permits
n acute or semi-acute assessment of xenobiotics on fetoplacental
icrovascular function, either through direct exposure of the iso-
ated fetoplacental blood vessels to the compound and assessment
f substance effects on vascular tone; or through overnight vessel
ulture with the test agent, followed by vascular tone assessment
he next day. Since the human placenta is not innervated, the func-
ional properties of isolated vessels reﬂect the endocrine milieu
mposed on the test system, as well as the autocrine and paracrine
ffects maintained within and between cells. This is an important
unctional assessment, because any constriction effects of xeno-
iotics on fetoplacental vascular tone relate to the impedance of
lood ﬂow between the placenta and the fetus, thereby restricting
xygen and nutrient delivery and impinging on fetal growth and
evelopment. Using existing data in a paired analysis, PlaNet could
xplore the capacity of chorionic plate resistance vessels to corre-
ate with the in vivo efﬁcacy of placental blood ﬂow through the use
f clinical indices of umbilical arterial Doppler velocimetry and fetal
rowth outcome data. In this HPTS, blood vessels (100–500 m
iameter) are representative of the stem villous microcirculation
nd are cut into 2 mm lengths; two steel wires are inserted into the
umen and wire ends secured to steel jaws; one wire is attached to a
orce transducer and the other to a movable micrometer. The wired
essel sits within a warmed bath containing gassed physiological
uffer. The diameter of the vessel lumen can be manipulated using
he micrometer and tension generated by constriction/stretch of
he vessel monitored via the force transducer. Active pressure of
he vessels is measured in response to agonists/xenobiotics and
elates to their contractility. Dose responses are easily acquired
ithin the preparation and arteries and veins can be evaluated
eparately. Vasoconstriction and vasodilation measurements can
e assessed and the potency of compounds to cause changes from
emporal vehicle control or inhibitor effects in a neighbouring bath
re reported [75,76]. Standardisation of placental myography pro-Please cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
ocols, with mutually agreed baseline and rejection thresholds,
mong over variables, is needed for toxicology testing applications.
he model does not represent vascular resistance within the full
illous tree. to an identiﬁed intact lobule (indicated by light shading; upward facing). There is
 employed, the mean tissue mass perfused, the buffer composition, the oxygenation
us perfusate goes to waste, or becomes recycled, respectively).
4.8. Cell culture
A variety of cell types can be isolated from the human placenta,
including primary trophoblast cells [77,78], placental microvascu-
lar endothelial cells [79] chorionic plate artery and vein endothelial
cells [80], ﬁbroblasts [81] and myocytes [82], to assess effects of
xenobiotics on their survival, division rates, apoptosis, endocrinol-
ogy, transporter activity and intracellular and second message
signalling. Dual cell culture systems, e.g.  trophoblasts with ﬁbrob-
lasts [83], or trophoblasts with endothelial cells [84,85] bring a level
of complexity enabling a study of effects of an agonist at the pri-
mary cell surface to evoke changes in cell–cell signalling and DNA
damage, affecting the second cell layer. This level of complexity is
considered further (see Section 4.11, below). Adoption of this tech-
nique depends on the development of harmonised protocols that
address cell line variability, particularly for primary trophoblast
cells. It should be noted that the behaviour of a single cell line may
change when isolated from the placenta, since it loses the paracrine
inﬂuence from other cell types. For instance, in most laboratories
trophoblast cells will only exhibit limited multinucleation.
4.9. Trophoblast spheroid cultures
The trophectoderm of the blastocyst differentiates into several
trophoblast subsets in order to create the placenta in the ﬁrst
trimester of pregnancy. Of these subsets, the cytotrophoblast is
considered a putative “progenitor cell,” which replenishes the outer
layer of the villous (syncytiotrophoblast). The extravillous tro-
phoblast necessarily invades the decidua in a cancer-like manner
to ensure that pregnancy is successful. Propagation of trophoblast
cells into spheroid aggregates under stem cell culturing condi-
tions conﬁrms the maintenance of the invading/progenitor status
of this cell type, proving its capacity for self-renewal. Cells with
self-renewing potential can be disaggregated from the spheroids
and passaged multiple times with retention of spheroid-forming
ability. This provides a potentially useful test in the safety testing
of xenobiotics, since interference with this spheroid renewal pro-
cess would infer dysregulation of the placental barrier and invasion
process. In the “hanging drop” protocol, tens of thousands of cells
can be amassed into a spheroid, recovered into single cells and re-
aggregated into spheroid cultures, or ﬁxed and immune-stained for
the existence of “stemness-” associated transcription factors OCT4,
NANOG, and SOX2; and for the trophoblast lineage, e.g.  cytokeratinnetwork (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
positivity. Early unpublished work indicates that the trophoblast
phenotype (e.g. hCG) is maintained in spheroid cultures, which can
be dysregulated by transcription and mitosis inhibitors. Spheroids
stained with tracer dye can also be assessed for their capacity to
 IN PRESSG ModelR
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Fig. 5. Diagrammatic model of “placenta on a chip”. Trophoblast cells and fetal
endothelial cells are grown on an amniotic membrane support in a chamber that
allows two  independent systems of medium ﬂow (arrows). The 3-D model allows
uptake studies from either compartment or transfer across the trilayer, as well as
endocrine sampling. The endothelial layer can be replaced by other cell types, as can
F
o
c
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nvade fresh placental explants within the hanging drop, providing
unctional data related to their “stemness” [86].
.10. Syncytiotrophoblast microvillous membranes
The maternal-blood facing microvillous membrane of the syncy-
iotrophoblast can be isolated from human placental homogenate
ollowing processing with magnesium precipitation, differential
entrifugation and characterisation of purity and reconstituted
orphology [87]. In conjunction with Mechaelis-Menton kinetics,
hey are particularly useful at characterising the presence and rela-
ive abundance of speciﬁc membrane transporters and the sodium
ependency of transfer [88]. However, data on regulatory potential
rom placental autocrine and paracrine inﬂuence is not possi-
le, because of the loss of intracellular organelles and signalling
achinery.
.11. Placenta on a chip
An alliance of placental physiologists, obstetricians, bioengi-
eers, computational and mathematical modellers would provide
 novel opportunity to begin to integrate tissue and cell cul-
ure systems on a micro-scale with real-time bioanalytical
ead-outs to recapitulate physiological responses of interest in
eproductive toxicology testing; however, the development of
 micro-engineered placenta is still in its infancy. Preliminary
ttempts to micro-fabricate the cellular environment of the pla-
enta, either in a multi-layered system to replicate placental barrier
unction, or as an organoid culture have shown promising poten-
ial, but these models require further characterisation with respect
o toxicology testing and need to be better coupled to real-time
nalysis [84–86]. Advances in this ﬁeld would facilitate xenobiotic
esting, inclusive of more simpliﬁed placental transfer experi-
ents and toxicology studies looking at effects on cell survival,
omeostatic regulation and endocrinology. Similar concepts have
lready been advanced for other organ systems including the lung,
here bio-mechanics to simulate breathing have been developed,Please cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
nabling studies on the exposure to nanoparticle stressors, with the
valuation of endothelial pro-inﬂammatory adhesion molecules
xpression and intracellular production of reactive oxygen species
89].
ig. 6. Cross sectional diagram of the human term placenta modiﬁed from Bottalico et al
f  monoamines in the fetal and maternal circulations. (I) Within the spiral arteries in-
ytokeratin positive cells (E), (II) surrounding the incoming spiral arteries (arrow) in-situ 
III)  In trophoblast cells of chorionic villi from the central part of the placenta in-situ hybr
 = 50um D = 120 um,  E,F = 220 um.the  chosen basement membrane.
Hamilton and others have simulated the placental barrier, under
ﬂow, using retinal epithelial pigment cells, to represent the placen-
tal trophoblast layer, and human umbilical vein endothelial cells
(HUVECs), replicating the placental microcirculation endothelium
(Fig. 5) [84]. They studied the pharmacokinetics of transfer of a
4KDa dextran tracer molecule, with a molecular radius approximat-
ing that which is sterically hindered by the placental barrier [28,30].
It was  discovered that the inclusion of human placental amnion
to form a third middle layer had the effect of supporting junc-
tional integrity [84]. This study demonstrates how a slightly more
complex system is supportive of paracrine interactions needed to
regulate cell junction interactions in micro-chip models. Indeed
this has been shown to be important in other organ-chip systems,
including studies on the blood-brain barrier [90]. In a follow up
study to the earlier Hamilton work, an in vitro biological model of
the placental barrier was constructed in another co-culture, this
time using the more tissue-speciﬁc immortalised human placental
trophoblasts and HUVECs on opposite sides of a denuded amni-
otic membrane [85]. In a further multi-layer cell barrier construct,network (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
involving exposing BeWo cells to nanoparticles, other investigators
have been able to demonstrate gap-junctional signalling leading to
. [101]. A hypothesised three line defence (I–III) against circulating excessive levels
situ hybridisation showed expression of VMAT 2 mRNA in darkﬁeld image (F) in
hybridisation showed expression of NET mRNA in brightﬁeld (C) and darkﬁeld (D).
idisation showed expression of SERT in brightﬁeld (A) and darkﬁeld (B). Scale bars:
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nﬂammatory cytokine release and DNA damage within the second
arrier layer [83].
Across many physiological systems, there are increasing efforts
n building multi-scale computational models that go hand-in-
and with reﬁned experimental models. Indeed, there has been
 recent surge in theoretical studies of placental morphology
91–93] and its relation to haemodynamics and transfer function
65,67,94–98]. We  now have the opportunity to combine the syn-
rgy of detailed inspection of placental barrier properties ex vivo
nd in vitro with the power of testing key mechanisms in silico that
hould accelerate the development of placenta-on-a-chip and its
ranslation to industrial and regulatory use.
The innovative aim of the network is to consider the design of
 multicellular placental system that could be used to derive real-
ime data on the effects of xenobiotics on placental function, since
lacenta health itself is vital in the support of fetal growth, devel-
pment and survival. In studying placental spheroids, or exploring
he role of microﬂuidics on anchored placental cells, it should be
ossible to obtain live bioanalytical data acquired by coupling bio-
ensors with the culture system. Raman spectroscopy, has so far
pplied to microbial detection, but perhaps is also adaptable to
n situ metabolic analysis [99]. The challenge is that outcome mea-
ures should be indicative of dysregulation of complex human
lacental physiology whilst permitting an efﬁcient appraisal of
arge compound libraries [100]. However, it should be borne in
ind that such “organ-on-a-chip” technology cannot easily rep-
esent of off-target effects of xenobiotics on other organ systems.
. Human placental drug handling in pregnancy
athologies
Placental barrier handling of xenobiotics, either by transporter
r efﬂux protein activity, could alter fetal exposures to drugs con-
equential of pregnancy pathologies such as preeclampsia and or
etal growth restriction (FGR). Deleterious effects on the fetus could
artly be explained by the failure of the placenta to clear both
ndogenous hormone/transmitter molecules or pharmaceuticals
nd other xenobiotic substances from the circulating milieu. An
xample of this relates to the trophoblast and stromal expres-
ion of the monoamine transporters: norepinephrine transporter
NET) and extra-neural monoamine transporter (EMT; or organic
ation transporter 3–OCT3) [101]. Monoamines play important
oles as physiological paracrine mediators in early pregnancy,
ncluding in decidualisation, implantation and immune modula-
ion, but dysregulated levels in early pregnancy risk miscarriage
102,103]. Unlike many other transmitter substances, monoamines
re recycled rather than enzymatically inactivated. In neuronal
issues, regulation of their extracellular milieu normally involves
heir compartmentalisation within neuronal synapses. Whilst the
lacenta is not innervated, NET, EMT  and vesicular monoamine
ransporter 2 (VMAT2) transporter types appear to serve to clear
onoamines from the maternal and fetal circulations. Bottal-
co discovered that both NET and EMT  mRNA expression was
educed in the central parts of human placentas delivered from
reeclamptic pregnancies, compared to those from normal preg-
ancy [104]. Speciﬁcally, reductions in the expression of these
ransporters in myoﬁbroblasts associated with large villous vessels
nd placenta septa might infer a loss of protection from circu-
ating levels of vasoactive monoamines which become elevated
n this disease. These loci normally represent the third line of
efence against excessive circulating monoamine levels, after NETPlease cite this article in press as: P. Brownbill, et al., An international 
for chemicals safety testing in pregnancy, Reprod Toxicol (2016), http
nd VMAT2 function in trophoblasts (that line the spiral arteries)
nd high levels of NET expression in trophoblasts lining spiral artery
ntrances (Fig. 6). In the non-innervated placenta, pseudo sympa-
hetic hyperactivity, consequential of poor NET and EMT  expression PRESS
xicology xxx (2016) xxx–xxx 9
in preeclampsia, might change placental haemodynamics by affect-
ing maternal and fetal blood ﬂow around and within placental
villi and could contribute towards the general elevation of blood
pressure within the fetal and maternal circulation [104]. From the
perspective of exploiting the placenta as a test model it should be
noted that, within the in vitro and ex vivo human placental tissue,
only the septa and villous vessel expression will remain (the third
line of monoamine defence), as the post-partum placenta is devoid
of spiral artery material.
Other extrinsic pathology factors affecting human placen-
tal drug transporter expression and activity include intrahepatic
cholestasis of pregnancy where the fetomaternal clearance of toxic
bile acids are reversed, leading to fetal accumulation of these sub-
stances [105,106]; and the down-regulation of apical transporters
and concurrent up-regulation of basal transporters during inﬂam-
matory conditions leads to decreased protection of the fetus from
toxic effects of xenobiotics [107,108]. It is therefore an essential
part of drug risk assessment in reproductive toxicology to under-
stand the effects of dysregulated drug transport on human placenta
accumulation and transport of compounds in the diseased state.
6. Innovation and future challenges in reproductive
toxicology testing
The outlined European placentology network, PlaNet, aims to
catalyse a concerted approach to testing the safety of chemicals for
the fetus as part of a group of assessments, using the most rele-
vant human placenta-based tools and procedures. This will only be
possible by crossing specialism boundaries and directly engaging
with end-users, such as the pharmaceutical industry and regulatory
authorities. The synergy and capacity within PlaNet will also allow
for a consideration of reproductive toxicology testing, accounting
for human variability in placental blood-barrier transfer dynam-
ics, as expected for (i) compromised pregnancies, such as fetal
growth restriction, preeclampsia, diabetes, intrahepatic cholesta-
sis of pregnancy and other inﬂammation related conditions; (ii)
cohorts with an unusual exposome, including high exposure to
environmental pollutants, that might have already conditioned the
placental phenotype; and (iii) genetic differences, including study-
ing cohorts of ethnic diversity and placental polymorphisms; where
placental handling of drugs and their derivatives and therefore sus-
ceptibility of the fetus to maternal medication might differ.
In addition to understanding placental transfer and using HPTSs
to complement current teratology methods, some HPTSs might
be suitable for high-throughput pre-reproductive toxicology triag-
ing testing of compounds, perhaps also reducing animal usage
to a degree in the longer term. However, developing appropriate
models and assays will be difﬁcult, requiring multi-disciplinary
collaboration, ensuring techniques are harmonised across many
centres and with the need for a proven reproducibility prior to stan-
dards being approved by regulatory authorities, including the EMA
and the FDA.
In the long term, such endeavours of the network will help
contribute to the data on safety in pregnancy labelling. From the
pharmaceutical industry’s perspective, the critical data that we  will
be able to facilitate on the pharmacokinetics of human placental
transfer will assist in more accurate “dosage margin setting” for
maternal medications, in conjunction with other data on “no- and
lowest observed-adverse-effect levels” (NOAELs/LOAELs) obtained
from animal testing [109]. This is pertinent to chemical compound
risk assessment reliability due to differences in placental com-network (PlaNet) to evaluate a human placental testing platform
://dx.doi.org/10.1016/j.reprotox.2016.06.006
partmentalisation between species [2] and other aforementioned
extrinsic human factors. In the long term, it could be that early stage
triage testing using the reviewed HPTSs may  lead to the reﬁnement
of animal use in toxicology testing. Liaison with organisations such
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s the European Centre for the Validation of Alternative Methods
ould advance our test systems towards endorsement by interna-
ional regulators.
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